Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Why is a Fever a Medical Emergency on JAK Inhibitors?

At a Glance

For children with Aicardi-Goutières syndrome taking JAK inhibitors, a fever of 100.4°F or higher is a strict medical emergency. These drugs suppress the immune system and can mask severe infections. Seek immediate emergency care with a specialist's emergency letter and physical medication bottles.

If your child with Aicardi-Goutières syndrome (AGS) is taking a JAK inhibitor, a fever of 100.4°F (38.0°C) or higher is considered a strict medical emergency. This is because the medication suppresses their immune system, which can hide or “mask” the typical warning signs of a severe illness. A fever could indicate either a rapidly progressing, life-threatening infection that your child’s body cannot fight off on its own, or a dangerous AGS inflammatory flare. Both scenarios require immediate medical evaluation, blood work, and often prompt treatment. While this is frightening, acting quickly and following a clear emergency plan ensures your child gets the targeted care they need for the best possible outcome.

How JAK Inhibitors Affect the Immune System

In AGS, the body produces too much type I interferon, causing chronic inflammation that damages the brain and other organs [1][2]. JAK inhibitors—such as baricitinib, ruxolitinib, or tofacitinib—work by targeting and calming down this overactive signaling pathway [3][4].

While these medications are highly effective at improving AGS symptoms like skin lesions and frequent fevers [5], they act as immunomodulators (drugs that alter how the immune system works) [6][7]. By turning down the immune system to stop it from attacking the body, JAK inhibitors also make it harder for the body to fight off everyday viruses, bacteria, and opportunistic infections [8][9].

The Danger of “Masked” Symptoms

Because JAK inhibitors alter immune function, your child might not look or act as sick as they actually are when an infection starts [10][11].

Furthermore, these medications can actively suppress the body’s warning signals. For example, some JAK inhibitors have been shown to potently lower the production of C-reactive protein (CRP) [12]. CRP is a key blood marker that emergency room doctors typically rely on to detect severe bacterial infections. If your child’s CRP response is blunted by their medication, an ER doctor unfamiliar with JAK inhibitors might falsely believe your child is not seriously ill, even while a dangerous infection is rapidly progressing.

Because fevers and CRP can both be masked, watch for other hidden signs of infection, such as:

  • Unusual lethargy, extreme fatigue, or difficulty waking up.
  • Changes in breathing (fast breathing, grunting, or working hard to breathe).
  • Decreased urination or refusal to drink fluids.
  • A sudden change in their neurological baseline (more seizures, increased irritability, or loss of recent skills).

Infection vs. AGS Flare

When a child with AGS develops a fever while on a JAK inhibitor, doctors face a critical diagnostic challenge. The fever could be caused by:

  • A severe infection: Which requires immediate targeted treatments (like IV antibiotics) because the child’s immune system is suppressed [13].
  • An AGS inflammatory flare: Which can also cause sudden fevers (febrile attacks) and widespread inflammation affecting multiple organs [14][15].

Because both situations can be life-threatening and require completely different treatments, doctors must perform a thorough clinical evaluation and blood work to rule out a hidden infection before assuming the fever is just a disease flare [16].

What to Do When Your Child Has a Fever (100.4°F / 38.0°C or higher)

If your child hits this temperature threshold, you must act quickly:

  • Do not wait it out: Seek immediate emergency medical care. Do not wait until morning or until the fever gets higher.
  • Do not give fever reducers: Unless explicitly instructed by your specialist, avoid giving acetaminophen or ibuprofen before heading to the ER. These medications can further mask the fever curve the doctors need to assess.
  • Hand over an Emergency Letter: ER doctors are much more likely to adapt their standard protocols when presented with a signed letter. Ask your AGS specialist to provide a formal “Emergency Care Letter” that details the diagnosis, the specific JAK inhibitor, the immunosuppressive risks, and the fact that the drug blunts CRP levels.
  • Bring the physical medication bottles: ER staff may be unfamiliar with specialty drugs like baricitinib or ruxolitinib. Having the physical bottles ensures exact dosing and name recognition.
  • Contact your specialist: Call your child’s neurologist or immunologist on your way to the ER so they can coordinate care directly with the emergency room physicians.

Common questions in this guide

What temperature is considered a medical emergency for a child on a JAK inhibitor?
A fever of 100.4°F (38.0°C) or higher is considered a strict medical emergency. You should seek immediate emergency medical care rather than waiting it out or waiting for the fever to get higher.
Why do JAK inhibitors make fevers so dangerous in AGS?
JAK inhibitors suppress the immune system to stop AGS-related inflammation. This makes it much harder for your child's body to fight off everyday viruses and severe bacterial infections, making rapid medical evaluation critical.
Can JAK inhibitors hide signs of an infection?
Yes, these medications can mask typical warning signs of severe illness. They can suppress fevers and artificially lower C-reactive protein (CRP), a common blood marker that emergency doctors use to detect severe infections.
Should I give my child fever-reducing medication before going to the ER?
Unless explicitly instructed by your specialist, avoid giving acetaminophen or ibuprofen before heading to the emergency room. These medications can alter the fever curve that doctors need to properly assess your child's illness.
What should I bring to the emergency room for an AGS fever?
You should bring a signed Emergency Care Letter from your specialist explaining your child's diagnosis and medication risks, along with the physical bottles of their JAK inhibitors to ensure exact dosing and name recognition.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you provide a signed 'Emergency Care Letter' detailing my child's AGS diagnosis, JAK inhibitor use, and the fact that their CRP levels may be artificially blunted?
  2. 2.What specific protocol should we follow regarding fever-reducing medications (like acetaminophen or ibuprofen) before we arrive at the ER?
  3. 3.Since JAK inhibitors can lower CRP levels, what alternative blood markers or tests do you recommend the ER use to reliably detect a severe infection?
  4. 4.How should we handle holding or continuing the JAK inhibitor dose during an active infection or fever?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Clinical spectrum and currently available treatment of type I interferonopathy Aicardi-Goutières syndrome.

    Dell'Isola GB, Dini G, Culpepper KL, et al.

    World journal of pediatrics : WJP 2023; (19(7)):635-643 doi:10.1007/s12519-022-00679-2.

    PMID: 36650407
  2. 2

    Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi-Goutières Syndrome, a Type I Interferonopathy.

    Meesilpavikkai K, Dik WA, Schrijver B, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2019; (71(5)):829-831 doi:10.1002/art.40805.

    PMID: 30666809
  3. 3

    Exploring emerging JAK inhibitors in the treatment of Aicardi-Goutières syndrome.

    Politano D, Tonduti D, Battini R, et al.

    Expert opinion on emerging drugs 2024; 1-19 doi:10.1080/14728214.2024.2445508.

    PMID: 39704072
  4. 4

    Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.

    Li W, Wang W, Wang W, et al.

    Frontiers in immunology 2022; (13()):825367 doi:10.3389/fimmu.2022.825367.

    PMID: 35418997
  5. 5

    Autosomal dominant ADAR c.3019G>A (p.(G1007R)) variant is an important mimic of hereditary spastic paraplegia and cerebral palsy.

    Jones HF, Stoll M, Ho G, et al.

    Brain & development 2022; (44(2)):153-160 doi:10.1016/j.braindev.2021.10.001.

    PMID: 34702576
  6. 6

    Pharmacological evaluation of drug therapies in Aicardi-Goutières syndrome: insights from patient-derived neural stem cells.

    Braidotti S, Ferraro RM, Franca R, et al.

    Frontiers in pharmacology 2025; (16()):1549183 doi:10.3389/fphar.2025.1549183.

    PMID: 40183101
  7. 7

    Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.

    Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S

    Nature reviews. Rheumatology 2022; (18(3)):133-145 doi:10.1038/s41584-021-00726-8.

    PMID: 34987201
  8. 8

    Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas.

    Pilmis B, Kherabi Y, Huriez P, et al.

    Cancers 2023; (15(7)) doi:10.3390/cancers15071989.

    PMID: 37046650
  9. 9

    Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.

    Ouranos K, Avila DV, Mylona EK, et al.

    PloS one 2024; (19(7)):e0306548 doi:10.1371/journal.pone.0306548.

    PMID: 39083492
  10. 10

    Macrophage re-programming by JAK inhibitors relies on MAFB.

    López-Navarro B, Simón-Fuentes M, Ríos I, et al.

    Cellular and molecular life sciences : CMLS 2024; (81(1)):152 doi:10.1007/s00018-024-05196-1.

    PMID: 38528207
  11. 11

    Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition.

    Raychaudhuri S, Cheema KS, Raychaudhuri SK, Raychaudhuri SP

    Current opinion in rheumatology 2021; (33(4)):348-355 doi:10.1097/BOR.0000000000000810.

    PMID: 34014847
  12. 12

    Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.

    Febvre-James M, Lecureur V, Fardel O

    Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2020; (69(1)):51-62 doi:10.1007/s00011-019-01293-1.

    PMID: 31654094
  13. 13

    Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.

    Szekanecz Z, Buch MH, Charles-Schoeman C, et al.

    Nature reviews. Rheumatology 2024; (20(2)):101-115 doi:10.1038/s41584-023-01062-9.

    PMID: 38216757
  14. 14

    Hepatic Involvement in Aicardi-Goutières Syndrome.

    Gavazzi F, Cross ZM, Woidill S, et al.

    Neuropediatrics 2021; (52(6)):441-447 doi:10.1055/s-0040-1722673.

    PMID: 33445189
  15. 15

    Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.

    Yu ZX, Song HM

    World journal of pediatrics : WJP 2020; (16(1)):44-51 doi:10.1007/s12519-019-00273-z.

    PMID: 31377974
  16. 16

    Aicardi-Goutières syndrome presenting with pneumocystis jirovecii pneumonia.

    Fogel LA, Bigley TM, Cole JJ, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2023; (34(6)):e13968 doi:10.1111/pai.13968.

    PMID: 37366204

This page provides emergency medical guidelines for educational purposes only. If your child takes JAK inhibitors and has a fever of 100.4°F or higher, go to the nearest emergency room immediately and contact your specialist.

Get notified when new evidence is published on Aicardi-Goutières syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.